)
)
Asarina Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Asarina Pharma
Access all reports
Asarina Pharma AB is a Swedish biotechnology company specializing in the development of Sepranolone, a compound designed to treat stress, compulsivity, and neurological disorders related to Allopregnanolone. This neurosteroid is implicated in conditions such as Tourette syndrome, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). Asarina Pharma's focus is on innovative treatments that modulate the effects of Allopregnanolone, aiming to provide safer and more effective therapeutic options. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
ASAP
Country
🇸🇪 Sweden